Skip to main content

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension

Clinical Trial Grant
Duke Scholars

Administered By

Medicine, Rheumatology and Immunology

Awarded By

X4 Pharmaceuticals

Start Date

February 21, 2020

End Date

November 30, 2022
 

Administered By

Medicine, Rheumatology and Immunology

Awarded By

X4 Pharmaceuticals

Start Date

February 21, 2020

End Date

November 30, 2022